HRMY · Harmony Biosciences Holdings, Inc. · Webcasts, Transcripts & Audio
$33.76
-0.04 (-0.12%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.98B
Shares
58.72M
Volume · Nov 13
844.92K
Avg daily vol (3M)
999.19K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Harmony Biosciences Holdings, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Harmony Biosciences Holdings, Inc. (HRMY), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
Revenue
$268.92M
▲ 12.3% YoY Diluted EPS
$0.81
▼ 6.9% YoY Gross margin
70.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-04
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript
Confident tone
Phase 1 PK and safety data for BP-205
WAKIX commercial performance and revenue growth
Upcoming data catalysts
Revenue
$261.28M
▲ 30.3% YoY Diluted EPS
$1.28
▲ 88.2% YoY Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Harmony Biosciences Holdings, Inc. (HRMY) June 9, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-09
Harmony Biosciences Holdings, Inc. (HRMY) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
Confident tone
BP-205 orexin-2 agonist pipeline
Business development strategy and capital deployment
Management transitions and leadership bench
Revenue
$215.39M
▲ 16.6% YoY Diluted EPS
$0.55
▼ 29.5% YoY Gross margin
79.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-13
Harmony Biosciences Holdings, Inc. (HRMY) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Confident tone
Late-stage pipeline and clinical catalysts
WAKIX commercial performance and blockbuster guidance
Pediatric narcolepsy approval and expansion
Revenue
$243.78M*
▲ 21.1% YoY Gross margin
71.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript
Confident tone
Pitolisant HD next-gen formulation
WAKIX commercial momentum
Pipeline setbacks and confidence
Revenue
$239.46M
▲ 28.7% YoY Diluted EPS
$0.87
▲ 10.1% YoY Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript
Confident tone
Pipeline and late-stage catalysts
WAKIX commercial performance
Fragile X / ZYN002 opportunity
Revenue
$200.49M
▲ 16% YoY Diluted EPS
$0.68
▲ 240% YoY Gross margin
81.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
Confident tone
WAKIX commercial performance in narcolepsy
ZYN002 in Fragile X Syndrome (RECONNECT)
Pitolisant HD next-generation formulation
Revenue
$184.73M
▲ 19.5% YoY Diluted EPS
$0.78
▲ 16.4% YoY Gross margin
82.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2024 Earnings Call Transcript
Confident tone
Pitolisant HD (next-generation) development
ZYN002 Fragile X program
Idiopathic Hypersomnia (IH) sNDA setback
Revenue
$201.27M*
▲ 19.5% YoY Gross margin
73.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
Confident tone
Rare epilepsy franchise (EPX-100, EPX-200)
Pitolisant franchise lifecycle (IH, GR, HD)
Late-stage pipeline and launches
Revenue
$186.04M
▲ 16.1% YoY Diluted EPS
$0.79
▲ 25.4% YoY Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call Transcript
Confident tone
WAKIX commercial performance
Pediatric narcolepsy launch
Pitolisant HD / life-cycle management
Revenue
$172.81M
▲ 28.8% YoY Diluted EPS
$0.20
▼ 64.3% YoY Gross margin
81.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2024 Earnings Call Transcript
Confident tone
TPM-1116 orexin-2 receptor agonist
WAKIX commercial performance
Pitolisant life cycle management & new indications
Revenue
$154.62M
▲ 29.8% YoY Diluted EPS
$0.67
▲ 39.6% YoY Gross margin
82.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript
Confident tone
WAKIX commercial growth and durability
Next-generation pitolisant formulations
Pediatric narcolepsy sNDA and pediatric exclusivity
Revenue
$168.41M*
▲ 31.3% YoY Gross margin
74.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2023 Earnings Call Transcript
Revenue
$160.27M
▲ 36.7% YoY Diluted EPS
$0.63
▼ 56.2% YoY Gross margin
79.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2023 Earnings Call Transcript
Revenue
$134.22M
▲ 25.4% YoY Diluted EPS
$0.56
▲ 43.6% YoY Gross margin
81.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2023 Earnings Call Transcript
Revenue
$119.13M
▲ 39.6% YoY Diluted EPS
$0.48
▲ 37.1% YoY Gross margin
82.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2022 Earnings Call Transcript
Revenue
$128.31M*
▲ 40.7% YoY Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript
Revenue
$117.21M
▲ 45.2% YoY Diluted EPS
$1.44
Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2022 Earnings Call Transcript
Revenue
$107.03M
▲ 45% YoY Diluted EPS
$0.39
▲ 62.5% YoY Gross margin
82.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2022 Earnings Call Transcript
Revenue
$85.31M
▲ 43% YoY Diluted EPS
$0.35
▲ 169.2% YoY Gross margin
82.8%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2021 Earnings Call Transcript
Revenue
$91.21M*
▲ 62% YoY Gross margin
80.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2021 Earnings Call Transcript
Revenue
$80.73M
▲ 77% YoY Diluted EPS
$-0.17
Gross margin
81.9%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2021 Earnings Call Transcript
Revenue
$73.82M
▲ 94.2% YoY Diluted EPS
$0.24
Gross margin
82.8%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2021 Earnings Call Transcript
Revenue
$59.67M
▲ 200.8% YoY Diluted EPS
$0.13
Gross margin
82.6%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2020 Earnings Call
Revenue
$56.29M*
Gross margin
82.4%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2020 Earnings Call
Revenue
$45.61M
Diluted EPS
$-0.14
Gross margin
82.7%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Showing 1–28 of 28 webcasts
Key facts
CIK
1802665
CUSIP
413197104
13F (30d)
283 filings
265 filers
Visit website
Investor relations